(IN BRIEF) Eckert & Ziegler and Ariceum Therapeutics have signed a global supply agreement for critical medical radionuclides Actinium-225 (Ac-225) and Lutetium-177 (Lu-177). The radionuclides will be used in Ariceum’s lead radiopharmaceutical drug, satoreotide, targeting hard-to-treat cancers such as small … Read the full press release
Posted in Business, Environment, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Ariceum Therapeutics, Critical Medical Radionuclides, Dr. Harald Hasselmann, Eckert & Ziegler, Healthcare, Manfred Rüdiger, partnership, sustainability
(IN BRIEF) The European Commission has approved Theralugand®, Eckert & Ziegler’s high-purity Lutetium-177 chloride, for routine clinical use across the European Economic Area. This approval allows its application in targeted cancer therapies, such as for neuroendocrine tumors and metastatic prostate … Read the full press release
Posted in Business, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged Cancer Therapies, Dr. Harald Hasselmann, Eckert & Ziegler, EU, Healthcare, safety, Theralugand®, wellness
(IN BRIEF) Eckert & Ziegler, in collaboration with Novartis Pharma K.K., is expanding Ga-68 labeled diagnostics in Japan through a clinical trial approved by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). Utilizing Eckert & Ziegler’s GalliaPharm® generator, the trial … Read the full press release
Posted in Business, Germany, Healthcare, Pharma & Biotech, Technology
Tagged clinical research project, clinical trial, computerized Tomography, diagnostics, DOTA-TATE Positron Emission Tomography, Dr. Harald Hasselmann, Eckert & Ziegler, Ga-68, GalliaPharm®, Gallium-68, Ge-68, Japan, Japanese Pharmaceuticals and Medical Devices Agency, NCT06240741, NEN, neuroendocrine neoplasms, Novartis Pharma K.K., PET, PMDA, radioisotope supply, rare tumors
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
